Last updated: May 24, 2026
Clopidogrel bisulfate is supplied globally as an oral solid API and as finished-dose tablets (typically 75 mg). The supply chain is bifurcated into (1) API manufacturers that produce clopidogrel bisulfate bulk drug substance and (2) finished-dose manufacturers and packaging supply chains for brand and generic tablets.
Which companies supply clopidogrel bisulfate (API) globally?
API supply is concentrated in a small set of large generics and specialty API makers plus multiple contract manufacturing and API intermediates suppliers. The most reliable way to map clopidogrel bisulfate “suppliers” for commercial use is to track:
- DMFs for clopidogrel bisulfate (bulk API) and associated API manufacturing sites
- US FDA-listed finished-dose suppliers (Orange Book)
- Global generic market participants producing clopidogrel tablets
What are the major clopidogrel bisulfate API manufacturers in the US FDA DMF system?
DMF holders and API manufacturing sites determine who supplies clopidogrel bisulfate API. For US market-facing procurement, the DMF landscape is typically mirrored by:
- API manufacturing locations listed under DMFs
- API release and testing sites used by finished-dose tablet manufacturers
Which companies supply clopidogrel bisulfate tablets (finished dosage form)?
Finished-dose tablets are supplied by branded and generic tablet manufacturers. Market access for clopidogrel 75 mg in the US is dominated by multiple generic manufacturers that buy or source clopidogrel bisulfate API and complete formulation, tablet compression, coating, and packaging.
Common tablet strengths and dosage form
- Strength: typically 75 mg (oral tablet)
- Formulation: immediate-release tablets (film-coated in many generic products)
What procurement focuses on for finished-dose tablets
- Tablet strength conformity and dissolution profile
- Impurity profile consistency for clopidogrel bisulfate
- Compliance with cGMP for finished drug product
How do API supplier choices affect generic clopidogrel 75 mg approvals?
Generic clopidogrel tablet approvals rely on demonstrating bioequivalence and maintaining an impurity profile consistent with the reference product. Supply chain implications:
API control points that drive regulatory outcomes
- Impurity control strategy (process-related and degradation impurities)
- Polymorph and particle size management (where specified in the dossier)
- Consistent salt form identity and stability
- Analytical method transfer and validation
What changes in API sourcing can trigger re-validation
- New API supplier qualification runs
- Stability bridging for the finished product
- Batch consistency demonstrations
Where does clopidogrel bisulfate supply come from geographically?
Supply is global across multiple manufacturing regions, with contracting patterns that often involve:
- API manufacturing in Asia (commonly China and India) and Europe
- Finished-dose manufacturing across the US, EU, and India
- Export and logistics intermediated by distributors and specialty pharma wholesalers
Which factors determine which clopidogrel bisulfate suppliers you should qualify?
For procurement and quality, qualifying “suppliers” depends on more than name recognition:
Regulatory and quality requirements
- cGMP history and inspection outcomes for API and finished-dose sites
- DMF and/or CEP availability for API
- Batch record control for critical process parameters
- Change control documentation (API process, site transfer, new suppliers)
Commercial and operational requirements
- Capacity availability for API and tablet compression/coating
- Lead times and safety-stock feasibility
- Supply continuity risk and alternative sourcing options
Who supplies clopidogrel bisulfate to US branded and generic markets?
In the US, procurement mapping is typically done through:
- Orange Book listings for clopidogrel 75 mg tablet products and their labeled manufacturers
- DMF linkages for API supply chains used by those manufacturers
- Contract manufacturing relationships embedded in product supply records
What generic entry risks exist if clopidogrel bisulfate API supply tightens?
If API supply constricts, finished-dose manufacturers face:
- Increased API cost volatility
- Delayed batch releases due to slower testing or supply interruptions
- Higher risk of unplanned formulation or sourcing changes that can require bridging and regulatory updates
How does clopidogrel bisulfate compare with other antiplatelet APIs for supply chain structure?
Clopidogrel bisulfate is chemically stable relative to many other classes, but the supply chain still depends on:
- Specialized intermediates for clopidogrel synthesis
- Proven impurity control in the final API
- Multiple qualified second-source paths to avoid single-site dependency
Key Takeaways
- Clopidogrel bisulfate is supplied through two layers: API manufacturers and finished-dose tablet producers.
- US-facing supplier qualification is best executed by mapping Orange Book finished-dose manufacturers to DMF-linked API manufacturing sites.
- Procurement decisions should focus on cGMP status, DMF/CEP support, impurity profile control, and demonstrated batch-to-batch consistency.
- API sourcing continuity matters because generic product timelines and batch release depend on analytical and stability bridging readiness.
FAQs
1) How do I identify the API supplier behind a specific clopidogrel 75 mg generic product?
Track the product’s listed manufacturer and cross-reference to the API DMF landscape used by that manufacturer’s submission and commercial sourcing chain.
2) Can clopidogrel bisulfate tablet manufacturers qualify multiple API suppliers?
Yes, but qualification requires batch consistency, impurity profile alignment, and stability and release test bridging for the finished product.
3) What documentation is typically required to qualify a new clopidogrel bisulfate API vendor?
Vendor qualification packages usually include cGMP evidence, DMF-related assurances, impurity specifications, CoA templates, and change-control commitments tied to process and site.
4) Do supplier changes affect dissolution and bioequivalence for generic clopidogrel?
They can. API sourcing changes may require additional comparability work, especially if impurity levels, particle attributes, or crystal form vary.
5) What should be checked for clopidogrel bisulfate API quality to prevent batch failures?
Impurity limits, identity and salt-form confirmation, stability indicators, and method suitability for release testing are the primary checks.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- U.S. FDA. Drug Master File (DMF) Program overview and public guidance documents on submissions and updates.
